Giuseppe Saglio
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 620
- Chronic Myeloid Leukemia Treatments 488
- Acute Myeloid Leukemia Research 135
- Genetics 468
- Chronic Lymphocytic Leukemia Research 339
- Myeloproliferative Neoplasms: Diagnosis and Treatment 78
- Hemoglobinopathies and Related Disorders 70
- Co-authors
- Andreas Hochhaus (85 shared papers)Hagop Kantarjian (51 shared papers)Timothy P. Hughes (58 shared papers)Michele Baccarani (72 shared papers)Daniela Cilloni (111 shared papers)Fabrizio Pane (65 shared papers)Jörge E. Cortes (43 shared papers)Giovanni Martinelli (99 shared papers)
- Journals
- Blood (241 papers)Leukemia (53 papers)British Journal of Haematology (47 papers)Haematologica (47 papers)Leukemia Research (15 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
Giuseppe Saglio
783 papers receiving 43.1k citations
Giuseppe Saglio's Hit Papers
Peers
Comparison fields: 5 of 161
- Hematology 33.0k
- Genetics 20.4k
- Rheumatology 10.8k
- Pathology and Forensic Medicine 4.5k
- Oncology 6.1k
Countries citing papers authored by Giuseppe Saglio
This map shows the geographic impact of Giuseppe Saglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Saglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Saglio more than expected).
Fields of papers citing papers by Giuseppe Saglio
This network shows the impact of papers produced by Giuseppe Saglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Saglio. The network helps show where Giuseppe Saglio may publish in the future.
Co-authors
The 25 scholars most cited alongside Giuseppe Saglio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 811 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2003 | 2905 |
| 2 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Hit paper breakdown → | 2006 | 2851 |
| 3 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Hit paper breakdown → | 2013 | 1614 |
| 4 | Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype Hit paper breakdown → | 2005 | 1576 |
| 5 | Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1381 |
| 6 | Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program Hit paper breakdown → | 2003 | 1313 |
| 7 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia Hit paper breakdown → | 2020 | 1080 |
| 8 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 1050 |
| 9 | Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease Hit paper breakdown → | 1999 | 995 |
| 10 | 2003 | 761 | |
| 11 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Hit paper breakdown → | 2016 | 756 |
| 12 | Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial Hit paper breakdown → | 2016 | 669 |
| 13 | 2008 | 468 | |
| 14 | BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet Hit paper breakdown → | 2011 | 444 |
| 15 | 2006 | 430 | |
| 16 | 2011 | 426 | |
| 17 | 1997 | 425 | |
| 18 | 2009 | 395 | |
| 19 | 2012 | 361 | |
| 20 | 2013 | 347 |
About Giuseppe Saglio
Giuseppe Saglio is a scholar working on Hematology, Genetics, Rheumatology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health, having authored 811 papers that have together received 44.7k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (488 papers), Chronic Lymphocytic Leukemia Research (339 papers), Eosinophilic Disorders and Syndromes (158 papers), Acute Myeloid Leukemia Research (135 papers), Acute Lymphoblastic Leukemia research (110 papers), Lymphoma Diagnosis and Treatment (88 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (78 papers) and Hemoglobinopathies and Related Disorders (70 papers). The work is most often cited by research in Hematology (33.0k citations), Genetics (20.4k citations), Rheumatology (10.8k citations), Pathology and Forensic Medicine (4.5k citations) and Oncology (6.1k citations). Giuseppe Saglio has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Andreas Hochhaus, Hagop Kantarjian, Timothy P. Hughes, Michele Baccarani, Daniela Cilloni, Fabrizio Pane, Jörge E. Cortes, Giovanni Martinelli, Enrico Gottardi and Richard A. Larson. Their work appears in journals such as Blood, Leukemia, British Journal of Haematology, Haematologica and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.